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a  b  s  t  r  a  c  t
A  randomized,  blinded,  negative  controlled  study  was  conducted  to determine  whether  treatment  with
afoxolaner  (NexGard®, Merial,  Inc.)  would  prevent  the  transmission  of  Borrelia  burgdorferi  to  dogs  by wild
caught  Ixodes  scapularis  ticks.  Twenty  healthy  dogs  were  randomly  assigned  to two  groups  of  ten  dogs
each.  Ten  dogs  were  treated  orally  on Day  0 at a dose  near  the  minimum  recommended  dose  of  afoxolaner
of  2.5  mg/kg  (actual  doses  2.5–3.1  mg/kg)  and  ten control  dogs  were  not  treated.  On  Day  28, each  dog  was
infested  with  approximately  50 adult  unfed  wild caught  I. scapularis  that  had  a 67% B.  burgdorferi  infection
rate  (determined  by  polymerase  chain  reaction).  On  Day 33, live  ticks  were  counted  and  removed.  No
ticks were  found  on  treated  dogs  while  control  dogs  had  an average  of  21.4  ticks.  To  detect  infection,  the
B. burgdorferi-speciﬁc  C6 antibody  SNAP® 4Dx® test  (IDEXX)  was  performed  on  serum  collected  before
infestation  (all  dogs  seronegative  on  Days  -6 and  27) and on Days  48, 63,  77 and  92. The  ten  treatedyme borreliosis
ransmission
revention
dogs  remained  seronegative  through  the  end of  the  study  (Day  92),  while  nine  out  of the  ten  control
dogs  were  infected,  as  demonstrated  by their seroconversion  to being  positive  for the presence  of the  B.
burgdorferi-speciﬁc  C6  antibody  starting  on  Day  48.  In  this  study,  all dogs  treated  with  NexGard® 28  days
prior  to challenge  with  wild caught  I.  scapularis  ticks  were  protected  from  B.  burgdorferi  infection,  while
ted  c
ublisnine out  of  the  ten untrea
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. Introduction
Lyme disease, also called borreliosis, is a tick-transmitted dis-
ase that affects humans and dogs in North America, Europe, and
sia. It is the most frequently diagnosed vector-borne disease in
umans and dogs in North America, where it is caused by the bac-
erial spirochete Borrelia burgdorferi sensu stricto,  with adult and
ymphal stages of Ixodes scapularis as principal vectors. Accord-
ng to Bowman et al. [1], B. burgdorferi-infected dogs can be found
n all 48 contiguous states of the United States of America (USA).
ased on serology, B. burgdorferi was most frequently detected in
ogs in the North-Midwest and Northeast of the USA, with an over-
ll prevalence of 11.6% in the Northeast, and pockets of up to 61%
eropositive dogs in the upper Midwest [1].
The regular use of acaricidal products may  reduce the risk of tick
ransmission of pathogens to dogs. It is assumed that the reduc-
∗ Corresponding author.
E-mail address: christine.baker@merial.com (C.F. Baker).
ttp://dx.doi.org/10.1016/j.cimid.2016.09.004
147-9571/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).ontrol  dogs  were  infected.
hed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tion of this risk is dependent on the speed of transmission of the
pathogens from the ticks to their hosts and the properties of the
ectoparasiticide being used, i.e., speed of kill, ability to prevent
tick attachment and/or repellent effect. Several topical acaricides
have been shown to reduce the risk of transmission of vector-
borne pathogens, i.e., Babesia, Borrelia, Ehrlichia, Anaplasma, and
published studies demonstrating the utility of tick control medi-
cations for dogs have focused on their acaricidal efﬁcacy against a
broad range of ixodid tick species [2–9].
Afoxolaner belongs to a new class of insecticides-acaricides,
the isoxazolines, which act systemically after dosing with an oral
formulation. Afoxolaner is highly bound to plasma proteins and
distributes into tissues, facilitating ingestion by hematophagous
arthropods when they feed. It acts as a ligand to a speciﬁc recep-
tor of both GABA and glutamate receptors of neuron synapses’ ion
chloride channels, inducing death of ﬂeas and ticks. The NexGard®oral formulation has been proven to provide plasma levels of afox-
olaner that quickly control ﬂea and tick infestations for a month on
dogs [10]. Its protective efﬁcacy against the transmission of Babesia
canis by Dermacentor reticulatus has been demonstrated recently
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Study design.
Study Day Event
-15 Begin acclimation of dogs; general health
observations at least once daily until the
conclusion of the study
-6 Weigh all dogs; conduct physical
examinations; collect blood samples from each
dog for IDEXX SNAP® 4Dx® testa
-2 Random allocation of dogs to treatment groups
-1 Remove food from all dogs (afternoon)
0  Treat dogs in Group 2 with NexGard®; observe
dogs hourly for ∼4 h after the last dog is
treated; feed dogs after completion of hourly
observations
27  Collect blood samples from each dog for IDEXX
SNAP®4Dx® test
28 Infest each dog with ∼50 Ixodes scapularis ticks
33 Count and remove ticks
48,  63, 77, 92 Collect blood samples from each dog for IDEXX6 C.F. Baker et al. / Comparative Immunology, M
3]. Based on previous studies demonstrating that NexGard killed
4% or more I. scapularis within 48 h after infestations conducted
p to 28 days after treatment [9], the objective of this study was to
ssess the protective efﬁcacy of NexGard® against the transmission
f B. burgdorferi to dogs by I. scapularis.
. Materials and methods
.1. Animal model and treatment
The study was conducted according to Good Scientiﬁc Prac-
ices and all animal procedures were reviewed and approved by
he Merial Institutional Animal Care and Use Committee (IACUC).
ogs were managed with due regard for their welfare, consistent
ith the US Animal Welfare Regulations (US Animal Welfare Regu-
ations, 2008, 9 CFR). The chronology of study activities is detailed
n Table 1.
This was a blinded, negative controlled clinical efﬁcacy study
sing a randomized block design. Twenty healthy purpose-bred
eagle dogs, 10 male and 10 female, 8.5 to 9 months old and not
reviously exposed to ticks or treated with any ectoparasiticide
rug were used. The dogs weighed 9 to 11.4 kg on Day -6. On Day
2, they were ranked by descending Day -6 body weight within sex.
en blocks of 2 dogs each were formed: the 2 male dogs with the
ighest body weight formed Block 1, the next 2 formed Block 2, and
o on, until all male dogs were allocated. The process was repeated
or the female dogs. Within blocks, dog were randomly allocated to
ne of two treatment groups by lottery (draw-from-the-hat).
The ten dogs in Group 1 were untreated control dogs and the
en dogs in Group 2 were treated once orally on Day 0 with a
ombination of NexGard® (Merial, Inc.) Chews to provide a dose
f afoxolaner as close as possible to the minimum recommended
ose of 2.5 mg/kg (actual doses ranged from 2.5 to 3.1 mg/kg, as
etailed in Table 2).
On Day 28, each dog was infested with approximately 50 adult,
nfed, wild-caught, I. scapularis (approximately 25 males and 25
emales) known to have a 67% B. burgdorferi infection rate (see Sec-
ion 2.2 next). The dogs were placed in clean individual containers
32 in. long, 19 wide and 13 high) and the ticks were placed on the
houlder area of each dog. The dogs remained in the container for
o longer than approximately 4 h, during which their safety and
omfort were monitored and the ticks were free to roam. Sedation
as allowed but was not needed.
The ticks were left on the dogs for 5 days in order to provide a
omplete meal and simulate the natural tick feeding behavior. On
ay 33, study personnel blinded to treatment assignments exam-
ned all dogs for the presence of live ticks, which they counted and
emoved (Table 3). Dogs were presented for tick counting in their
ousing order, which was not related to their treatment group. The
ive or dead status of each tick was assessed before the removal of
he ticks with forceps. If an attached tick appeared to be dead, it
as assessed again after its removal from the animal to conﬁrm
ts live/dead status. Once the entire body of the animal had been
xamined for ticks, the animal was combed using a ﬂea comb to
nsure that all ticks had been counted and removed.
.2. Ticks and tick infection rates
Adult, unfed wild I. scapularis were collected in a known
ndemic area in southern Rhode Island (USA) between 26 October
nd 15 November 2014. Polymerase chain reaction (PCR) was used
o determine the B. burgdorferi infection rate in the ticks based
n a representative sample of 30 ticks (15 females and 15 males)
elected randomly from 6 different tick storage vials. DNA was
uriﬁed using a modiﬁcation of the DNeasy® blood and tissue kitSNAP®4Dx® test
a IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine, USA.
protocol from Qiagen (Qiagen, Inc., Valencia, CA, USA). Individ-
ual ticks were placed in 1.5 mL microcentrifuge tubes containing
180 L of tissue lysis buffer. Ticks were crushed using a disposable
1000 L pipette tip with its tip heat sealed. After crushing, 20 L of
proteinase K were added and samples were incubated for 2 h in a
55 ◦C water bath. The DNeasy tissue extraction protocol was then
followed, as described by the manufacturer.
PCR ampliﬁcations to detect B. burgdorferi sensu stricto were then
performed using Primers A2 [5′ GTT TTG TAA TTT CAA CTG CTG ACC
3′] and A4 [5′ CTG CAG CTT GGA ATT CAG GCA CTT C 3] following
published methods [11], and results showed that the wild caught
I. scapularis used in this study had a B. burgdorferi infection rate of
67%.
2.3. Serology
Blood (approximately 4 mL)  was collected from each dog on
Days -6 and 27 to conﬁrm that they were seronegative for B.
burgdorferi prior to allocation, treatment and infestation. After
infestation on Day 28, blood samples were collected from all dogs
as indicated in Table 1. At each time point, the blood samples were
placed in individually labelled serum separator tubes. Serum was
recovered, and tested using the IDEXX SNAP®4Dx®Test to detect
C6 B. burgdorferi antibody, according to the manufacturer’s instruc-
tions.
2.4. Statistical methods
2.4.1. Tick counts
Efﬁcacy with respect to live tick counts was  calculated using
the formula [(C − T)/C] × 100, where C and T are the arithmetic
means of the control and treated group, respectively. The popu-
lation means of the two  treatment groups were compared using an
F-test adjusted for the allocation blocks used to randomize the ani-
mals to the two  treatment groups. This was performed by analyzing
the natural logarithm of (counts + 1) using the Mixed procedure in
SAS Version 9.4 with Treatment used as the only ﬁxed effect, and
Blocks used as the random effect.
2.4.2. Serology
The proportion of SNAP®4Dx® test-positive animals in theNexGard® group was compared to the proportion of positive ani-
mals in the control group at each time point using both the Pearson
chi square test as well as the Cochran–Mantel–Haenszel test (CMH).
The Pearson chi square test compares the difference of the propor-
C.F. Baker et al. / Comparative Immunology, Microbiology and Infectious Diseases 49 (2016) 65–69 67
Table  2
Treatment Details.
Dog Identiﬁcation Day -6 Body
Weight (kg)
Number of 0.5 g
NexGard® Chewsa
Number of 1.25 g
NexGard® Chewsa
Afoxolaner Dosage
(mg/kg)
970 11.24 NAb NA NA
971  11.18 NA NA NA
972  11.14 NA NA NA
967  9.92 NA NA NA
973  9.82 NA NA NA
979  11.24 NA NA NA
982  10.16 NA NA NA
977  9.88 NA NA NA
981  9.86 NA NA NA
983  9.18 NA NA NA
968  11.42 3 0 3.0
974  11.16 0 1 2.5
969  11.01 0 1 2.6
966  10.42 0 1 2.7
964  9.02 0 1 3.1
978  10.64 0 1 2.7
976  10.29 0 1 2.8
975  9.92 0 1 2.9
985  9.60 0 1 2.9
984  9.34 0 1 3.0
ains 28.3 mg of afoxolaner.
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Table 3
Counts of Live Ixodes scapularis on Dogs, Retention Rate and Analysis of Live I. scapu-
laris Counts at Day 33.a
Dog ID Block Treatment
Group
Live Tick
Counts
Tick Retention
Rateb
970 1 1 25 50.0%
971  2 1 28 56.0%
972  3 1 21 42.0%
967  4 1 18 36.0%
973  5 1 22 44.0%
979  6 1 16 32.0%
982  7 1 16 32.0%
977  8 1 23 46.0%
981  9 1 24 48.0%
983  10 1 21 42.0%
Group 1 Arithmetic Mean: 21.4 42.8%
968  1 2 0 0.0%
974  2 2 0 0.0%
969  3 2 0 0.0%
966  4 2 0 0.0%
964  5 2 0 0.0%
978  6 2 0 0.0%
976  7 2 0 0.0%
975  8 2 0 0.0%
985  9 2 0 0.0%
984  10 2 0 0.0%
Group 2 Arithmetic Mean: 0 0.0%
Percent Efﬁcacyc: 100% (p < 0.001d)
a Each dog was infested with approximately 50 unfed adult Ixodes scapularis
(approximately ½ males and ½ females) on Day 28. Ticks were removed and live
ticks were counted 5 days after infestation on Day 33.
b Tick retention rate (estimated) = Number of Live Ticks counted on the dog on
Day 33 divided by 50 (50 = approximate number of infesting ticks placed on each
dog on Day 28).
c The percent efﬁcacy was computed using the formula [(C − T)/C] × 100, where
C  and T are the listed mean for the control and treated group, respectively.a 0.5 g NexGard® Chewable contains 11.3 mg  of afoxolaner; 1.25 g Chewable cont
b NA = not applicable.
ions while the CMH  compares the ratio of positives in the treated
o the Control group, with the latter test evaluating relative risk.
oth tests were computed using the Freq procedure in SAS Version
.4. Statistical comparisons were made using a 0.05 signiﬁcance
evel.
. Results
Study Day 33 tick counts and analyses are presented in Table 3.
o live tick was found on any of the ten dogs treated with
exGard®, while an average of 21.4 I. scapularis were removed from
he ten untreated control dogs. NexGard® treatment provided 100%
ercent efﬁcacy at 5 days after tick infestations, compared to the
ontrol group, and the population means of the two  groups were
igniﬁcantly different (p ≤ 0.001).
The individual SNAP®4Dx® C6 B. burgdorferi antibody test
esults are presented in Table 4 and results of analyses of these
ata are presented in Table 5. All twenty dogs were seronegative
rior to allocation and treatment and prior to tick infestation. The
rst Borrelia-seropositive dog was observed in the control group
n Day 48 and the number of positive dogs in the control group
ncreased until the end of the study. By Day 92, nine of the ten
ontrol dogs were seropositive, while none of the ten NexGard®
reated dogs became seropositive at any time during the study.
here was a signiﬁcant difference in the expected proportion of
ositive between the control and the NexGard® groups on Days 63,
7, and 92 on both the Pearson chi-square test (p ≤ 0.003) and the
ochran–Mantel–Haenszel test (p ≤ 0.004).
No clinical signs of Lyme disease were detected in any of the
ogs during the daily health observations conducted at least once
aily through the end of the study on Day 92.
. Discussion
Results of this study conﬁrm the high level of efﬁcacy of Nex-
ard against challenge with Ixodes scapularis ticks, as reported in
ther studies where the product was shown to be highly effective
gainst this and other Ixodes species within 48 h of challenge, for
p to a month [4,9]. Leaving the ticks on the dogs for 5 days after
hallenge allowed time for surviving ticks to take a natural and
omplete blood meal, which resulted in the infection of 9 out of thed (Two-sided) p-values comparing the population means of the control and
treated groups.
ten control dogs with B. burgdorferi and conﬁrmed the validity of
this transmission model.
As expected after an experimental infestation, a percentage of
infesting ticks did not remain on their host, either because they
were not ready to attach, or because they were groomed off by the
host. Male ticks are especially susceptible to removal because they
attach at a lesser rate than females. The 36–56% (average 42.8%)
68 C.F. Baker et al. / Comparative Immunology, Microbiology and Infectious Diseases 49 (2016) 65–69
Table 4
Borrelia Burgdorferi C6 antibodies SNAP® 4Dx® Results.
Dog ID and Treatment Group Resultsa Day -6b Day 27b Day 48 Day 63 Day 77 Day 92
970 −c − − − + +
971  − − − + + +
972  − − − − + +
967  − − + + + +
973  − − − + + +
979  − − − − − −
982  − − − − − +
977  − − − + + +
981  − − − + + +
983  − − − + + +
Number of Positive Dogs in untreated Group 1: 0 0 1 6 8 9
968  − − − − − −
974  − − − − − −
969  − − − − − −
966  − − − − − −
964  − − − − − −
978  − − − − − −
976  − − − − − −
975  − − − − − −
985  − − − − − −
984  − − − − − −
Number of Positive Dogs in NexGard®treated Group 2: 0 0 0 0 0 0
a ID: Identiﬁcation (n = 10 dogs per treatment group).
b Day -6 and Day 27 samples collected before the tick infestations on Day 28.
c ‘+’ = positive; ‘−’ = negative.
Table 5
Proportion and Analysis of the Number of Dogs Positive for Borrelia burgdorferi C6
Antibody on SNAP®4Dx® .
Study Number Positivea P-Valuesb
Day Control NexGard® Pearsonc Relative Riskd
27 0/10 0/10 1.000 1.000
48 1/10 0/10 0.305 0.317
63 6/10 0/10 0.003 0.004
77 8/10 0/10 <0.001 <0.001
92 9/10 0/10 <0.001 <0.001
a Number of dogs positive for B. burgdorferi over total number of dogs tested in
Group.
b (Two-sided) probability value that the two treatment groups had different pop-
ulation rates.
c Pearson: Pearson chi square used to compare the difference of the two propor-
t
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cions.
d Relative risk test of the ratio of the treated to control proportions using the
ochran–Mantel–Haenszel test.
ick retention rate on untreated control dogs at 5 days after infes-
ation was well above the 20% minimum required to demonstrate
he vigorousness of infesting ticks and the validity of the calculation
f effectiveness against ticks [20].
The absence of clinical signs of Lyme disease through the end
f this study at 64 days after tick infestations (Study Day 92) is in
ccordance with three previous laboratory studies using a simi-
ar B. burgdorferi transmission model [5,8,12], where sporadic and
pisodic clinical signs of Lyme disease were observed in only one
og (lameness on days 74, 76, 90 and 92 days after tick infesta-
ion) [12]. Similarly, the majority of dogs naturally infected with B.
urgdorferi do not develop clinical signs of Lyme disease [15].
Infection is a pre-requisite for disease to develop and our study
ocused on the demonstration of B. burgdorferi infection by detect-
ng dogs that acquired the C6 peptide of B. burgdorferi,  a speciﬁc
arker of natural B. burgdorferi infection in dogs [13–18]. The
DEXX SNAP® 4Dx® test was chosen because of its extensive use
n the ﬁeld and its 96.7% sensitivity and 98.8% speciﬁcity for C6 B.
urgdorferi antibodies [13].
The quantitative OspA or C6 antibody tests used by Wagner and
olleagues may  have allowed for the detection of seroconversion atearlier time points than did the SNAP 4Dx test, but this did not seem
necessary since the dogs were being monitored for seroconversion
though Day 92, i.e. 64 days after tick infestations [12]. In Wagner’s
study, all dogs had seroconverted to positive SNAP 4Dx by 49 days
after infestation [12].
Orally administered and systemically distributed insectici-
dal/acaricidal molecules, such as afoxolaner require that ticks
attach and begin feeding before being killed. Infection with
pathogenic agents can be reduced by killing ticks quickly, before
transmission occurs. For B. burgdorferi, transmission is thought to
occur between 36 and 72 h after tick attachment to the host [19].
This study conﬁrmed that afoxolaner was able to kill all I. scapu-
laris ticks on treated dogs before they could transmit B. burgdorferi.
A similar level of prevention was  observed against Babesia canis
transmission by D. reticulatus ticks in another recent study with
Nexgard® [3].
In this study, a single treatment with NexGard® administered at
a dose close to the minimum recommended dose of 2.5 mg/kg afox-
olaner 28 days prior to tick infestation, protected dogs against the
transmission of B. burgdorferi, the causative agent of Lyme disease,
from naturally infected I. scapularis ticks.
Disclaimer
This document is provided for scientiﬁc purposes only.
NexGard® is a registered trademark of Merial. Any reference to a
brand or trademark herein is for informational purposes only and
is not intended for a commercial purpose or to dilute the rights of
the respective owner(s) of the brand(s) or trademark(s).
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